Analyst Price Target is $38.17
▲ +439.08% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Avidity Biosciences in the last 3 months. The average price target is $38.17, with a high forecast of $71.00 and a low forecast of $20.00. The average price target represents a 439.08% upside from the last price of $7.08.
Current Consensus is
The current consensus among 6 contributing investment analysts is to buy stock in Avidity Biosciences. This Buy consensus rating has held steady for over two years.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.